Who Exports Mycophenolate from India — 167 Suppliers Behind a $334.4M Market
India's mycophenolate export market is supplied by 167 active exporters who collectively shipped $334.4M across 2,529 shipments. INTAS PHARMACEUTICALS LIMITED leads with a 61.7% market share, followed by STRIDES PHARMA SCIENCE LIMITED and ALKEM LABORATORIES LIMITED. The top 5 suppliers together control 93.1% of total export value, reflecting a concentrated market structure.
Top Mycophenolate Exporters from India — Ranked by Export Value
INTAS PHARMACEUTICALS LIMITED is the leading mycophenolate exporter from India, holding a 61.7% share of the $334.4M market across 2,529 shipments from 167 exporters. The top 5 suppliers — INTAS PHARMACEUTICALS LIMITED, STRIDES PHARMA SCIENCE LIMITED, ALKEM LABORATORIES LIMITED, SANDOZ PRIVATE LIMITED, EMCURE PHARMACEUTICALS LIMITED — collectively control 93.1% of total export value, indicating a highly concentrated market. Individual shares are: INTAS PHARMACEUTICALS LIMITED (61.7%), STRIDES PHARMA SCIENCE LIMITED (10.5%), ALKEM LABORATORIES LIMITED (8.8%), SANDOZ PRIVATE LIMITED (7.9%), EMCURE PHARMACEUTICALS LIMITED (4.2%).
Top Mycophenolate Exporters from India
Ranked by export value · 167 active suppliers · Indian Customs (DGFT) data
| # | Supplier & Formulations | Value | Ctry. | Share |
|---|---|---|---|---|
| 1 | INTAS PHARMACEUTICALS LIMITED MYCOPHENOLATE MOF 500MG 100FCT BO US MATMYCOPHENOLATE MOFETIL TABLETS USP [500MGPHARMA DRUGS AND MEDI MYCOPHENOLATE MOFE | $206.5M | 24 | 61.7% |
| 2 | STRIDES PHARMA SCIENCE LIMITED MYCOPHENOLATE MOF 500MG 100FCT BO US MATMYCOPHENOLATE MOFETIL TABLETS USP [500MG | $35.0M | 3 | 10.5% |
| 3 | ALKEM LABORATORIES LIMITED MYCOPHENOLATE MOF 500MG 100FCT BO US MATMYCOPHENOLATE MOFETIL TABLETS USP [500MGMYCOPHENOLATE SDZ 500MG 50FCT AU MATERIA | $29.3M | 9 | 8.8% |
| 4 | SANDOZ PRIVATE LIMITED MYCOPHENOLATE MOF 500MG 100FCT BO US MATMYCOPHENOLATE MOFETIL TABLETS USP [500MGMYCOPHENOLATE SDZ 500MG 50FCT AU MATERIA | $26.5M | 8 | 7.9% |
| 5 | EMCURE PHARMACEUTICALS LIMITED PHARMA DRUGS AND MEDI MYCOPHENOLATE MOFEMYCOPHENOLATE MOFETIL 500MG- 5X10 TAB (EMYCOPHENOLATE 250MG 50HGC V1 CA MATERIAL | $14.0M | 23 | 4.2% |
| 6 | CONCORD BIOTECH LIMITED MYCOPHENOLATE MOF 500MG 100FCT BO US MATMYCOPHENOLATE MOFETIL TABLETS USP [500MG | $6.9M | 8 | 2.1% |
| 7 | PANACEA BIOTEC PHARMA LIMITED | $4.0M | 9 | 1.2% |
| 8 | MYLAN LABORATORIES LIMITED MYCOPHENOLATE MOF 500MG 100FCT BO US MATMYCOPHENOLATE MOFETIL TABLETS USP [500MG | $2.6M | 4 | 0.8% |
| 9 | INTAS PHARMACEUTICALS LTD MYCOPHENOLATE MOF 500MG 100FCT BO US MATMYCOPHENOLATE MOFETIL TABLETS USP [500MGPHARMA DRUGS AND MEDI MYCOPHENOLATE MOFE | $975.9K | 6 | 0.3% |
| 10 | ALKEM LABORATORIES LTD MYCOPHENOLATE MOF 500MG 100FCT BO US MATMYCOPHENOLATE MOFETIL TABLETS USP [500MGMYCOPHENOLATE SDZ 500MG 50FCT AU MATERIA | $929.5K | 3 | 0.3% |
| 11 | SOLIS LIFE CARE LLP | $922.2K | 1 | 0.3% |
| 12 | ACME GENERICS PRIVATE LIMITED MYCOPHENOLATE 250MG 50HGC V1 CA MATERIALMYCOPHENOLATE 250MG 50HGC V1 CA MATERIALNO. - 44096937MYCOPHENOLATE 250MG 50HGC V1 CA, MATERIAL NO. - 44096937 | $612.4K | 1 | 0.2% |
| 13 | LA RENON HEALTHCARE PRIVATE LIMITED MYCOPHENOLATE MOF 500MG 100FCT BO US MATMYCOPHENOLATE MOFETIL TABLETS USP [500MGPHARMA DRUGS AND MEDI MYCOPHENOLATE MOFE | $604.5K | 4 | 0.2% |
| 14 | EMCURE PHARMACEUTICALS LTD PHARMA DRUGS AND MEDI MYCOPHENOLATE MOFEMYCOPHENOLATE MOFETIL 500MG- 5X10 TAB (EMYCOPHENOLATE 250MG 50HGC V1 CA MATERIAL | $476.6K | 3 | 0.1% |
Related Analysis
Supplier Certification & Compliance Matrix
FDA, WHO-GMP, and EU GMP status for top Mycophenolate exporters
| Supplier | US FDA | WHO-GMP | EU GMP | ANDAs | Notes |
|---|---|---|---|---|---|
| Intas Pharmaceuticals Limited | Approved | Yes (April 2007) | Yes | Multiple | FDA approval for multiple drugs; WHO-GMP certified in April 2007; EU GMP complia |
| Strides Pharma Science Limited | Approved | Unknown | Unknown | Multiple | FDA approval for multiple drugs; no FDA warning letters found. |
| Alkem Laboratories Limited | Approved | Unknown | Unknown | Multiple | FDA approval for multiple drugs; no FDA warning letters found. |
| Emcure Pharmaceuticals Limited | Approved | Unknown | Unknown | Multiple | FDA approval for multiple drugs; no FDA warning letters found. |
| Panacea Biotec Pharma Limited | Unknown | Yes (June 2023) | Unknown | Unknown | WHO-GMP certified in June 2023; no FDA warning letters found. |
| Mylan Laboratories Limited | Approved | Unknown | Unknown | Multiple | FDA approval for multiple drugs; no FDA warning letters found. |
| Concord Biotech Limited | Approved | Unknown | Unknown | Multiple | FDA approval for multiple drugs; no FDA warning letters found. |
| Sandoz Private Limited | Approved | Unknown | Unknown | Multiple | FDA approval for multiple drugs; no FDA warning letters found. |
TransData Nexus reviewed the regulatory standing of 8 leading Mycophenolate exporters from India. 7 hold US FDA facility approvals, 2 maintain WHO-GMP certification, and 1 are EU GMP compliant. For regulated markets (US, EU, Australia), prioritise suppliers with active FDA or EU GMP approvals. For semi-regulated markets (Africa, ASEAN, Latin America), WHO-GMP certification is the minimum recommended standard.
Certification status compiled from publicly available regulatory databases including FDA Orange Book, WHO Prequalification database, and EMA GMP registry. Buyers should independently verify compliance status with the relevant regulatory authority before placing orders.
TransData Nexus Research · Mar 2026
Manufacturing Hub Analysis — Vendor Proximity
India's pharmaceutical clusters relevant to Mycophenolate sourcing
1Hyderabad — Bulk Drug Capital
Hyderabad, often referred to as the "Bulk Drug Capital of India," contributes over 40% of the country's bulk drug production. The city hosts more than 2,000 pharmaceutical companies, including major players like Dr. Reddy's Laboratories and Aurobindo Pharma. The establishment of Hyderabad Pharma City, recognized as a National Investment Manufacturing Zone in December 2019, further solidifies its position as a pharmaceutical hub.
2Ahmedabad-Vadodara — Formulations Hub
The Ahmedabad-Vadodara corridor in Gujarat is renowned for its pharmaceutical formulations and biogenerics manufacturing. Vadodara, in particular, is home to numerous pharmaceutical companies, contributing significantly to the state's pharmaceutical output. The region's focus on formulations makes it a strategic location for companies involved in the production of finished dosage forms.
3Mumbai-Thane-Raigad — Export Gateway
The Mumbai-Thane-Raigad belt serves as a crucial export gateway for India's pharmaceutical industry. Mumbai, being a major port city, facilitates the export of pharmaceutical products to global markets. The region's well-established infrastructure and proximity to international shipping routes make it an ideal location for companies aiming to expand their global footprint.
4Baddi-Nalagarh — Tax Incentive Zone
Baddi-Nalagarh in Himachal Pradesh has emerged as a significant pharmaceutical cluster, primarily due to favorable tax incentives offered by the state government. This region attracts numerous pharmaceutical companies seeking cost-effective manufacturing solutions, thereby contributing to the overall growth of India's pharmaceutical sector.
5Sourcing Recommendations
- Diversify Supplier Base: While INTAS PHARMACEUTICALS LIMITED dominates Mycophenolate exports, consider engaging with other top exporters like STRIDES PHARMA SCIENCE LIMITED and ALKEM LABORATORIES LIMITED to mitigate supply chain risks.
- Leverage Regional Strengths: Utilize Hyderabad's bulk drug manufacturing capabilities for sourcing active pharmaceutical ingredients (APIs) and Ahmedabad-Vadodara's expertise in formulations for finished dosage forms.
- Optimize Logistics: Capitalize on the Mumbai-Thane-Raigad region's export infrastructure to streamline shipping processes and reduce lead times for international markets.
- Explore Cost Benefits: Investigate manufacturing opportunities in the Baddi-Nalagarh region to take advantage of tax incentives and potentially lower production costs.
By strategically engaging with these pharmaceutical clusters, companies can enhance their supply chain resilience and capitalize on India's robust pharmaceutical manufacturing ecosystem.
Recent M&A, Collaborations & Capacity Expansions
Industry developments among top Mycophenolate exporters from India
Intas Pharmaceuticals Limited — Intas acquires Teva's UK & Ireland assets for $764 million
In October 2016, Intas Pharmaceuticals Limited acquired the UK and Ireland assets of Teva Pharmaceuticals for $764 million. This strategic acquisition expanded Intas's presence in the European market, enhancing its portfolio and manufacturing capabilities. IMPACT: The acquisition bolstered Intas's production capacity, potentially increasing Mycophenolate exports to European markets.
Impact: The acquisition bolstered Intas's production capacity, potentially increasing Mycophenolate exports to European markets.
Intas Pharmaceuticals Limited — Intas sets up new manufacturing facility in PHARMEZ
In March 2021, Intas Pharmaceuticals Limited established a new manufacturing facility in PHARMEZ (Bavla, near Ahmedabad) with the capacity to manufacture and export over 1 billion solid dosages and 5 million injectables. This expansion aimed to meet growing global demand. IMPACT: The increased production capacity may lead to higher Mycophenolate export volumes.
Impact: The increased production capacity may lead to higher Mycophenolate export volumes.
Intas Pharmaceuticals Limited — Intas acquires Sanofi's Fawdon manufacturing site
In January 2018, Intas Pharmaceuticals Limited, through its subsidiary Accord Healthcare, acquired Sanofi's manufacturing site in Fawdon, UK. This acquisition added a fifth manufacturing location in the UK, enhancing Intas's production capabilities. IMPACT: The acquisition expanded Intas's manufacturing footprint, potentially increasing Mycophenolate production for export.
Impact: The acquisition expanded Intas's manufacturing footprint, potentially increasing Mycophenolate production for export.
Common Questions — Mycophenolate Suppliers from India
Answers based on Indian Customs (DGFT) shipment records compiled by TransData Nexus
Q Which mycophenolate supplier from India is the most reliable for bulk orders?
Based on shipment frequency and export consistency, INTAS PHARMACEUTICALS LIMITED leads with 454 recorded shipments worth $206.5M. STRIDES PHARMA SCIENCE LIMITED (193 shipments) and ALKEM LABORATORIES LIMITED (356 shipments) are also established high-volume exporters.
Q How many mycophenolate manufacturers are there in India?
India has 167 active mycophenolate exporters with a combined export market of $334.4M across 2,529 shipments to 100 countries. The top 5 suppliers hold 93.1% of total export value.
Q What certifications should I verify?
Verify: WHO-GMP certification (most markets), US FDA approval (United States), EU GMP certificate (EU/EEA), and Free Sale Certificate from CDSCO. Always request a Certificate of Analysis (CoA) and Certificate of Origin (CoO).
Q What is the typical price range for mycophenolate from India?
Average FOB unit price: $15.03 per unit, ranging from $0.00 to $400.57. Average shipment value: $132.2K.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Supplier Ranking: 167 verified Indian exporters of Mycophenolate ranked by capped export value from DGFT shipping bill records.
- 2.Export Value Analysis: Total export value aggregated from 2,529 individual shipping bill records. Values are FOB in USD.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation.
- 4.Market Concentration: Supplier market share and geographic reach analyzed across 100 destination countries.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
2,529 Verified Shipments
167 exporters tracked
Expert-Reviewed
By pharmaceutical trade specialists